--- title: "Zepbound vs Mounjaro: Same Drug?" description: "Zepbound vs Mounjaro: both are tirzepatide, so why two brands? The FDA-approved uses, dose differences, and what it means. Find out." canonical: https://remevihealth.com/blog/zepbound-vs-mounjaro-weight-loss/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-06-10T00:00:00.000Z updatedDate: 2026-06-10T00:00:00.000Z tags: ["Zepbound", "Mounjaro", "tirzepatide", "GIP", "GLP-1", "FDA approval", "weight loss"] alternateLanguage: https://remevihealth.com/es/blog/zepbound-vs-mounjaro/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/zepbound-vs-mounjaro-weight-loss/ as the source." --- Zepbound and Mounjaro come in the same kind of pen, from the same manufacturer, and both contain tirzepatide. Yet they are two different prescriptions, and mixing them up can cost you weeks of insurance back-and-forth. The reason there are two names is the single most useful thing to understand before you ask a clinician about either one. This is a science-first explainer of why one molecule carries two brand names, what each product is FDA-approved to treat, the mechanism they share, and what the clinical trials measured. Individual results vary, and nothing here is medical advice. ## One molecule, two labels Tirzepatide is the active ingredient inside both pens. Eli Lilly developed it once, then took it through two separate FDA review processes, because US drug approvals are organized around a question that surprises most people: not "what is this molecule?" but "what condition is it approved to treat?" When the FDA approved tirzepatide in May 2022 to improve blood sugar in type 2 diabetes, the product got the name Mounjaro. When the agency later approved tirzepatide for chronic weight management in November 2023, that indication launched under a second name: Zepbound. Two approvals, two labels, one molecule. This is not unusual. Semaglutide works the way: Ozempic and Wegovy are both FDA-approved semaglutide products from Novo Nordisk, split along the same diabetes-versus-weight-management line. If you want that side of the story, our breakdown of [Zepbound vs Wegovy compared](/blog/zepbound-vs-wegovy/) covers it. The split matters in practice for one big reason: insurance. Coverage decisions track the indication on the label. A plan that covers tirzepatide for diabetes under Mounjaro may handle a weight-management prescription under Zepbound completely differently. The name on the prescription has to match the condition being treated. ## What each one is FDA-approved for The cleanest way to keep them straight is by indication, per each product's FDA prescribing information: **Mounjaro (tirzepatide)** is approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes. Per the current FDA label, that now includes adults and pediatric patients 10 years of age and older. **Zepbound (tirzepatide)** is approved for chronic weight management in adults with obesity (BMI of 30 or higher), or overweight (BMI of 27 or higher) with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. In December 2024 the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication ever approved for that condition. That sleep apnea approval is worth pausing on, because it shows how indication-driven this system is. In the two 52-week trials behind it, adults with obstructive sleep apnea and obesity who received tirzepatide had significantly fewer breathing interruptions per hour of sleep (measured by the apnea-hypopnea index) than those on placebo, and the FDA noted the improvement is likely related to the weight reduction itself. Same molecule, same mechanism, a third condition, and it landed on the Zepbound label rather than a new name because it was studied in the weight-management population. ## The mechanism both pens share Whatever the label says, the biology inside is identical. Tirzepatide is a dual agonist: a single engineered molecule that activates two incretin receptors at once, GIP and GLP-1. Those are receptors for two gut hormones your body releases after you eat, and together they influence appetite signaling, how quickly your stomach empties, and how your body handles insulin after meals. ![Tirzepatide molecule shown as the shared active ingredient in Zepbound and Mounjaro](https://remevihealth.com/images/molecules/helix-tirze.webp) *The tirzepatide molecule: one engineered peptide that activates both the GIP receptor and the GLP-1 receptor. This same structure sits inside every Zepbound and Mounjaro pen; only the FDA-approved indication on the label differs.* A GLP-1-only medication such as semaglutide activates one of those receptors. Tirzepatide engages both, which appears to amplify the appetite and metabolic effects beyond what GLP-1 alone produces. If you want the receptor-level detail, our explainer on [how tirzepatide works](/blog/how-tirzepatide-works/) goes deeper, and our side-by-side on [semaglutide vs tirzepatide](/semaglutide-vs-tirzepatide/) compares the one-receptor and two-receptor approaches directly. The point for the Zepbound-versus-Mounjaro question: there is no "stronger" or "weaker" version between these two products. Dose for dose, the pharmacology is the same. ## Dose and titration: also the same Both products use the identical dosing ladder, per their FDA prescribing information. Treatment starts at 2.5 mg injected once weekly, a dose meant for initiation rather than maintenance. After four weeks it moves to 5 mg, and from there a clinician can step up in 2.5 mg increments, holding each level for at least four weeks, up to a maximum of 15 mg once weekly. For Zepbound, the recommended maintenance doses are 5, 10, or 15 mg. The slow ramp is deliberate. Gastrointestinal side effects such as nausea, diarrhea, and constipation are the most common with tirzepatide, and they cluster around dose increases. Stepping up gradually gives the body time to adjust, and not everyone needs to reach the top dose; the right maintenance level is the one that balances effect and tolerability for that person. ## What the trials measured The headline evidence behind the weight-management indication is SURMOUNT-1, a 72-week randomized, placebo-controlled trial of 2,539 adults with obesity, or overweight plus a weight-related complication, published in the New England Journal of Medicine in 2022. Participants on tirzepatide saw average reductions of roughly 16% of body weight on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, versus about 2.4% with placebo. Around 89% of those on 5 mg and 96% on the higher doses lost at least 5% of body weight, compared with 28% on placebo. These are trial averages over a defined study window, not a forecast for any individual, and individual results vary. On the diabetes side, SURPASS-2 compared tirzepatide head-to-head against semaglutide 1 mg over 40 weeks in 1,879 adults with type 2 diabetes, also in NEJM. All three tirzepatide doses produced greater average reductions in A1C and body weight than semaglutide at that dose, with broadly similar rates of gastrointestinal side effects. Again: averages from a diabetes population, attributed to the trial, with individual variation built into every one of those curves. Notice that none of this evidence distinguishes Zepbound from Mounjaro. The trials studied tirzepatide. The brand names simply mark which body of evidence the FDA reviewed for which condition. ## How a clinician decides which fits you In practice, the choice between these two labels is rarely a preference question. It follows from diagnosis and coverage: If you have type 2 diabetes and the goal is glycemic control, the prescription is written as Mounjaro. If you do not have diabetes and the goal is weight management, or treatment of obstructive sleep apnea with obesity, the prescription is written as Zepbound. A clinician confirms the indication, screens your history (including contraindications such as a personal or family history of medullary thyroid carcinoma), checks what your insurance will actually do, and then plans the titration. Cost is where many people first feel the difference between the labels, since coverage for weight management is often narrower than coverage for diabetes. Some patients explore compounded tirzepatide through licensed US compounding pharmacies for cost or access reasons. If that option comes up, precision matters: compounded tirzepatide is a separate, non-FDA-approved preparation, distinct from both branded products, and the trial evidence described above belongs to tirzepatide as studied in those branded trials. The disclosure at the end of this article states the distinction in full. Our guide to [how tirzepatide works and who it fits](/tirzepatide/) walks through how a REMEVi clinician evaluates all of this. ## The answer in one line Zepbound and Mounjaro contain one active ingredient, tirzepatide, dosed on one schedule, built on one mechanism; what separates them is the FDA-approved indication on each label, which determines who each product is approved to treat and how insurance handles it. The right one for you is whichever matches your diagnosis, and that is a decision to make with a licensed clinician, not a search result. **Your Health. Your Terms.** Talk to a real clinician at [remevihealth.com](/tirzepatide/). --- *This article is for general information and does not constitute medical advice. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Individual results vary. Consult a licensed provider before starting any prescription treatment.*